Johns Hopkins University and MedImmune, the global biologics research and development arm of AstraZeneca, today announced a first-of-its-kind PhD training program between a major university and a biopharmaceutical company in the United States.
The Johns Hopkins-MedImmune Scholars Program, part of an ongoing collaboration between the university and biopharmaceutical company, will prepare JHU graduate students for careers in the biomedical workforce. Program participants will gain research experience in an industry environment, be introduced to the drug discovery and development process, and complete a yearlong internship at MedImmune.
{iframe}http://hub.jhu.edu/2016/03/02/hopkins-medimmune-graduate-training-program{/iframe}